COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Submission of Matters to a Vote of Security Holders
Submission of Matters to a Vote of Security
Coherus BioSciences, Inc. (the Company) held its 2017 Annual
Meeting of Stockholders (the Annual Meeting) on May17, 2017. On
the March24, 2017 record date, there were 51,288,027 shares of
the Companys common stock outstanding with each such share being
entitled to one vote per share.
At the Annual Meeting, 38,482,506 shares of the Companys common
stock were voted in person or by proxy for the three proposals
set forth below, each of which is described in the Companys
Definitive Proxy Statement on Schedule 14A filed with the U.S.
Securities and Exchange Commission on April6, 2017.
Proposal 1. The Companys stockholders elected
the Class III director nominees below to the Companys Board of
Directors to hold office until the 2020 Annual Meeting of
Stockholders or until their successors are elected.
|FOR||WITHHELD||BROKER NON- VOTES|
Dennis M. Lanfear
James I. Healy M.D., Ph.D.
Proposal 2. The Companys stockholders ratified
the selection of Ernst Young LLP as the independent registered
public accounting firm of the Company for its fiscal year ending
Proposal 3. A non-binding advisory resolution to
approve our executive compensation (a Say on Pay vote).
On May16, 2017, the Company issued a press release reporting that
the Patent Trial and Appeal Board of the U.S. Patent and
Trademark Office ruled in favor of Coherus petitions for Inter
Partes Review of AbbVies U.S. Patent 8,889,135. A copy of the
press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated by reference into this Item8.01.
|Item9.01||Financial Statements and Exhibits.|
|99.1||Press release dated May 16, 2017.|
About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs). COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Recent Trading Information
COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) closed its last trading session down -2.20 at 22.30 with 984,966 shares trading hands.